AOA Dx
AOA Dx, headquartered in New York, NY, and Cambridge, MA, is a healthcare company specializing in early cancer detection technologies, particularly focusing on ovarian cancer through innovative blood tests like GlycoLocate™ and AKRIVIS GD™.
Company Overview
AOA Dx, previously known as AOA Dx Inc., is located in New York, NY and Cambridge, MA, with remote operations. The team consists of six members, and the company operates within the healthcare industry, specifically focusing on diagnostics. AOA Dx is dedicated to innovation in women's health, primarily through the early detection of ovarian cancer.
Innovative Cancer Detection Technologies
AOA Dx offers a groundbreaking blood test for the early detection of ovarian cancer. The company is developing GlycoLocate™, a revolutionary tumor marker ganglioside platform, and AKRIVIS GD™, a novel blood test leveraging tumor marker gangliosides for early-stage ovarian cancer detection. These innovative technologies aim to significantly improve early cancer detection, showcasing high sensitivity and specificity in retrospective studies.
Research and Development Partnerships
AOA Dx collaborates with leading researchers at McGill University to pioneer early-stage ovarian cancer diagnostics. This partnership has resulted in the development of the first liquid biopsy diagnostic test for early-stage ovarian cancer. The company’s focus on collaboration and advanced research emphasizes its commitment to addressing critical needs in women's health.
Media and Industry Recognition
AOA Dx has been featured in notable publications and media outlets, highlighting its innovations in the healthcare and diagnostics sectors. The company’s advancements in early cancer detection and ongoing research have garnered attention from industry leaders and media, underscoring its impact in women's health diagnostics.
Funding and Investment
In its pursuit of advancing diagnostic technologies, AOA Dx raised a $7M Seed round. This investment supports the company’s efforts to develop and refine its novel ganglioside tumor marker platform, facilitating further research and innovation in early cancer detection.
